Video content above is prompted by the following: (PINKERTON) Sleep has been identified as an independent symptom from hot flashes. With the emerging research regarding the use of elinzanetant to combat sleep disturbances associated with menopause [such as anticipated data […]
The Importance of Sleep in Menopause Management Read More »
Panelists express their gratitude for the informative discussion and share their final thoughts on the evolving landscape of menopause management and the potential impact of new therapies on improving patient outcomes. Source link Ryan Haumschild, PharmD, MS, MBA, CPEL
Closing Thoughts: Evolving Treatment Paradigms in Menopause Management Read More »
Video content above is prompted by the following: (PINKERTON) Elinzanetant was studied in the OASIS 1 and 2 trials, and new data on OASIS 3 were just presented at The Menopause Society’s 2024 Annual Meeting. What was the methodology of
Quality of Life and Symptom Relief Read More »
Video content above is prompted by the following: (PINKERTON) What notable adverse events were observed in the OASIS trials with elinzanetant? (FIFFICK) How do these safety profiles of elinzanetant and fezolinetant compare with traditional treatments? Source link Ryan Haumschild, PharmD,
Safety Profiles of Neurokinin-Targeted Therapies for VMS Read More »
Video content above is prompted by the following: (SMITH) The approval of fezolinetant for moderate to severe VMS was based on the SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4 trials. Briefly describe the methodology of these studies. (FIFFICK) What were
Key Findings From the SKYLIGHT Trials Read More »
Video content above is prompted by the following: (PINKERTON) What is the role of neurokinin in the pathophysiology of vasomotor symptoms? (SMITH) Fezolinetant is a nonhormonal novel agent now available for the treatment of moderate to severe VMS due to
A Focus on the Neurokinin Pathway Read More »
Video content above is prompted by the following: (FIFFICK) What steps can be taken to improve treatment rates of VMS associated with menopause? (SMITH) How does the intersection of socioeconomic status and access to health care resources influence the management
Improving Access and Equity in VMS Treatment Read More »
Video content above is prompted by the following: (FIFFICK) Considering the significant comorbidities often associated with menopause, such as cardiovascular disease and osteoporosis, how should VMS treatment be integrated into a broader health management plan for women? Source link Ryan
Integrating VMS Treatment Into Comprehensive Women’s Health Management Read More »
Video content above is prompted by the following: Let’s begin by discussing the impact of VMS related to menopause and the large number of people affected. According to the SWAN[Study of Women’s Health Across the Nation] data, up to 80%
Understanding the Burden of Menopausal Vasomotor Symptoms Read More »
Video content above is prompted by the following: What underlying factors do you think contribute to the persistent under-treatment of VMS in menopausal women, despite the high prevalence of these symptoms? What factors contribute to patient resistance to conventional VMS
Barriers to VMS Treatment and Impact on Long-Term Health Read More »
